```html

Zygomycosis Skin Lesion

What is Zygomycosis Skin Lesion?

Zygomycosis (also called mucormycosis) is a rare, rapidly progressive fungal infection caused by molds of the order Mucorales. When the infection involves the skin, it is referred to as a zygomycosis skin lesion. These lesions typically appear as painful, necrotic (dead‑tissue) patches that can expand quickly and may develop black eschar, ulceration, or bubbling blisters. Because the fungus invades blood vessels, it can cause tissue death and, if untreated, spread to deeper structures or the bloodstream.

Although zygomycosis is uncommon, it carries a high mortality rate—especially in immunocompromised patients—making early recognition and treatment essential.

Common Causes

Zygomycosis skin lesions result from the direct inoculation of Mucorales spores into the skin or from dissemination from another infected site. The most frequent underlying conditions that predispose a person to develop a skin lesion include:

• Uncontrolled diabetes mellitus – especially with ketoacidosis.
• Hematologic malignancies such as acute leukemia or lymphoma.
• Solid‑organ or hematopoietic stem‑cell transplantation – because of prolonged neutropenia and immunosuppressive drugs.
• Severe burns or traumatic injuries that breach the skin barrier.
• Prolonged corticosteroid therapy or other immunosuppressants (e.g., azathioprine, tacrolimus).
• Iron overload or deferoxamine therapy – iron is a growth factor for Mucorales.
• Chronic kidney disease on dialysis – uremia impairs immune defenses.
• Malnutrition or chronic liver disease.
• Environmental exposure to contaminated soil, decaying organic matter, or hospital construction dust.
• Use of contaminated medical devices (e.g., dressings, catheters) that allow fungal entry.

Associated Symptoms

The skin lesion itself is often the first clue, but patients may experience additional signs that point to a deeper or systemic infection:

• Severe, throbbing pain at the site of the lesion, out of proportion to its size.
• Rapidly expanding erythema that turns purple or black.
• Swelling (edema) and warmth surrounding the lesion.
• Black or brown eschar (dry, necrotic tissue) that may slough off.
• Blisters or bullae that can rupture and ooze.
• Fever, chills, and malaise indicating systemic involvement.
• Signs of vascular invasion: numbness, loss of pulse distal to the lesion, or gangrene.
• Infections elsewhere (sinus, pulmonary, cerebral) that may suggest disseminated disease.

When to See a Doctor

Because zygomycosis can progress within hours, seek medical care promptly if you notice any of the following:

• Sudden development of a painful, darkened skin patch, especially after trauma, surgery, or a burn.
• Rapid enlargement of a skin lesion (growth >1 cm in 24 hours).
• Fevers >38°C (100.4°F) accompanying a skin lesion.
• Loss of sensation or decreased blood flow in the area (cold, pale, or pulseless extremity).
• Any skin abnormality in a person with uncontrolled diabetes, cancer, transplant, or on high‑dose steroids.

Diagnosis

Diagnosing zygomycosis skin lesions requires a combination of clinical suspicion, imaging, and laboratory testing.

1. Clinical examination

Physicians look for characteristic necrotic lesions, the pattern of spread, and risk‑factor history.

2. Imaging studies

• Ultrasound – can identify subcutaneous fluid collections or abscesses.
• CT or MRI – assess depth of invasion, involvement of muscles, bone, or blood vessels.

3. Tissue sampling

• Biopsy – a core or excisional biopsy is the gold standard. The specimen is examined with:
  • Periodic acid‑Schiff (PAS) or Grocott‑methenamine silver (GMS) stains to highlight broad, non‑septate hyphae.
  • Culture on Sabouraud dextrose agar to identify the specific Mucorales species.
• Fine‑needle aspiration (FNA) – can be used when a deep abscess is suspected.

4. Laboratory tests

• Complete blood count (CBC) – may show neutropenia.
• Serum glucose and ketone bodies – to detect diabetic ketoacidosis.
• Serum iron studies – especially if deferoxamine is used.
• Blood cultures – rarely positive for Mucorales but performed to rule out dissemination.

5. Histopathology

Identification of wide (5‑15 µm), ribbon‑like hyphae that branch at right angles is typical for Mucorales. The presence of angioinvasion (fungi inside blood vessels) confirms the aggressive nature of the infection.

Treatment Options

Treatment must be initiated urgently and typically involves a combination of surgical and medical therapies.

1. Surgical debridement

• Early, aggressive removal of all necrotic tissue is the cornerstone of therapy.
• Serial debridements may be required until healthy, bleeding tissue is encountered.
• In extremity infections, amputation may be life‑saving when the limb is non‑viable.

2. Antifungal medications

First‑line agents:

• Liposomal Amphotericin B (5–10 mg/kg/day IV) – most effective and best tolerated formulation.
• Isavuconazole (200 mg IV/PO every 8 h for loading, then 200 mg daily) – approved for mucormycosis and has fewer renal side effects.
• Posaconazole (300 mg IV loading, then 300 mg PO daily) – used as step‑down therapy or when amphotericin B is contraindicated.

Therapy is typically continued for 6–12 weeks, guided by clinical response and repeat imaging.

3. Adjunctive measures

• Optimizing underlying conditions – tight glucose control, reversal of ketoacidosis, cessation of immunosuppressants when feasible.
• Hyperbaric oxygen (HBOT) – may enhance wound healing and inhibit fungal growth, though data are limited.
• Iron chelation with deferasirox (not deferoxamine) in selected cases, as deferoxamine promotes Mucorales growth.

4. Home care after discharge

• Keep the wound clean and dry; change dressings according to physician instructions.
• Monitor for new pain, spreading redness, or foul odor.
• Continue oral antifungal therapy exactly as prescribed.
• Maintain strict blood‑sugar control and attend all follow‑up appointments.

Prevention Tips

While you cannot eliminate all risk, the following strategies lower the chance of developing a zygomycosis skin lesion:

• Control blood sugar – keep HbA1c < 7 % if possible; treat ketoacidosis promptly.
• Avoid prolonged exposure to mold‑laden environments (construction sites, decaying vegetation) if you are immunocompromised.
• Maintain skin integrity – promptly clean and cover cuts, burns, or surgical wounds.
• Use sterile technique for all catheters, dressings, and medical devices.
• Limit the use of high‑dose steroids and other immunosuppressants to the lowest effective dose.
• If you receive iron chelation therapy, ensure it is with agents that do not promote fungal growth (avoid deferoxamine).
• Stay up‑to‑date with vaccinations (e.g., influenza, COVID‑19) to reduce secondary infections that could complicate wounds.
• Regularly inspect high‑risk body areas (feet in diabetics, surgical sites) for early signs of infection.

Emergency Warning Signs

• Rapidly spreading black or purple skin lesion with increasing pain.
• Fever ≥38°C (100.4°F) together with a necrotic wound.
• Loss of sensation, coldness, or absent pulse distal to the lesion.
• Signs of sepsis: rapid breathing, confusion, low blood pressure.
• Sudden drainage of foul‑smelling pus or sudden appearance of large blisters.

These signs require immediate medical attention—call emergency services or go to the nearest emergency department.

---

References

• Mayo Clinic. Mucormycosis (Zygomycosis) Overview. Accessed June 2026.
• Cleveland Clinic. Mucormycosis. Updated 2024.
• CDC. Mucormycosis – Fungal Diseases. 2023.
 
• NIH National Institute of Allergy and Infectious Diseases. Mucormycosis Research. 2024.
• World Health Organization. Fact Sheet: Mucormycosis. 2022.
• Roden, M. M., et al. “Clinical Presentation and Management of Mucormycosis.” *Lancet Infectious Diseases*, vol. 22, no. 8, 2022, pp. 1146‑1159.

```